
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech has demonstrated significant growth, with sales of surgical soft tissue repair products increasing by 24% year-over-year to $23.4 million, driven by heightened demand for its CellerateRX Surgical product. The company is also on track for sustainable revenue growth, anticipating topline growth of 3-5% in 2025 and an impressive 13-17% in 2026, supported by a lucrative contract with Vizient that enhances access to its BIASURGE product line. Additionally, Sanara's operational improvements and strategic partnerships, including an Innovative Technology contract with Vizient, position the company for continued financial success and enhanced market presence in the wound care sector.
Bears say
Sanara MedTech Inc reported net revenue of $26.3 million, which reflects a year-over-year growth of 21.5%, although this figure fell short of the projected revenue of $26.7 million. The company faces multiple risks that may adversely affect its financial performance, including lower-than-expected revenue growth, challenges in acquiring new customers, difficulties in launching new products or services, and potential dilution risks. Additionally, there has been a significant reduction in the company's enterprise value to revenue multiple from 4.3x to 3.0x, driven by the exclusion of telehealth from its business model, indicating a shift in market perception and potential valuation concerns.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares